Welcome to our dedicated page for Kineta SEC filings (Ticker: KA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Kineta's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Kineta's regulatory disclosures and financial reporting.
Kineta (KA) filed a Form 4 disclosing that director Shawn Iadonato exercised 237,500 stock options on 06/23/2025 at strike prices of $0.36 and $0.611, actions triggered by full vesting upon shareholder approval of the TuHURA Biosciences merger.
To cover taxes, 52,353 shares were sold at $0.26 (Code F). Net of the sale, his direct holdings rose to 860,377 shares; combined with 8,553 shares held via an IRA, total beneficial ownership is 868,930 shares, a ~27% increase.
The transactions were contractual (Code M) rather than open-market purchases, signalling alignment but offering limited insight into insider sentiment.